Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 11/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 11/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22773732 | 0.82 | CYP4F2 (0.49) | CYP4F2CYP4A11PLA2G4BL3MBTL1GAA | |
| SCHEMBL22787195 | 0.81 | LMNA (0.39) | CYP4F2CYP4A11L3MBTL1GAAPDE2A | |
| SCHEMBL22787130 | 0.81 | LMNA (0.39) | CYP4F2CYP4A11L3MBTL1GAAPDE2A | |
| SCHEMBL29526638 | 0.81 | LMNA (0.39) | CYP4F2CYP4A11L3MBTL1GAAPDE2A | |
| SCHEMBL21098734 | 0.76 | PPARD (0.53) | — | |
| SCHEMBL22787237 | 0.74 | MAPT (0.43) | L3MBTL1 | |
| SCHEMBL13980911 | 0.73 | MAPT (0.55) | CYP4F2CYP4A11PLA2G4BL3MBTL1PPARA | |
| SCHEMBL15382193 | 0.71 | L3MBTL1 (0.50) | PLA2G4BL3MBTL1GAA | |
| SCHEMBL31448501 | 0.70 | PPARA (0.65) | PLA2G4BL3MBTL1GAAPPARA | |
| SCHEMBL18611552 | 0.70 | HTR1B (0.47) | L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020248065-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-17 | — | — | WO | disclosed |